Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 2/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.51 |
| ▸ | APLNR | P35414 | 2/20 | 0.50 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.49 |
| ▸ | GNRHR | P30968 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teprotide SCHEMBL613590 | 1.00 | F13A1 (0.52) | F13A1TGM2CXCR4APLNRABCC2 | |
| Teprotide SCHEMBL8158703 | 0.97 | CXCR4 (0.51) | F13A1TGM2CXCR4APLNRABCC2 | |
| SCHEMBL11872216 | 0.96 | GNRHR (0.50) | F13A1TGM2CXCR4APLNRABCC2 | |
| SCHEMBL11867492 | 0.94 | GNRHR (0.51) | F13A1TGM2CXCR4APLNRABCC2 | |
| Teprotide SCHEMBL613757 | 0.92 | GNRHR (0.57) | F13A1TGM2APLNRABCC2GNRHR | |
| SCHEMBL11863118 | 0.89 | IL23R (0.51) | F13A1TGM2CXCR4CTSLCTSS | |
| SCHEMBL11863142 | 0.89 | IL23R (0.51) | F13A1TGM2CXCR4CTSLCTSS | |
| SCHEMBL24120770 | 0.87 | CXCR4 (0.55) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL11865471 | 0.86 | CXCR4 (0.46) | F13A1TGM2CXCR4APLNRABCC2 | |
| SCHEMBL11872436 | 0.86 | CASP1 (0.51) | CXCR4CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3947575-A | Peptides as argiotensin converting enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1976-03-30 | — | — | US | claimed |
| US-20180164289-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2018-06-14 | — | — | US | disclosed |
| US-3973006-A | Peptide enzyme inhibitors of angiotensin I | E. R. SQUIBB & SONS, INC. (US) | 1976-08-03 | — | — | US | disclosed |
| US-3947575-A | Peptides as argiotensin converting enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180164289-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | SENP8, SENP6, SENP7 | F13A1 2652/4885TGM2 1002/4885CXCR4 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.